EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan

Hirokazu Yano iD, Wataru Hayashi iD, Sayoko Kawakami, Sadao Aoki, Eiko Anzai, Hui Zuo, Norikazu Kitamura iD, Aki Hirabayashi iD, Toshiki Kajihara iD, Shizuo Kayama iD, Yo Sugawara iD, Koji Yahara iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 02.05.2024 · 68 (5)

DOI: 10.1128/aac.01669-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.05.2024. Verfasst von Hirokazu Yano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Microbial Sensitivity Tests, Carbapenems, Anti-Bacterial Agents. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Japan is a country with an approximate 10% prevalence rate of carbapenem-resistant Pseudomonas aeruginosa (CRPA). Currently, a comprehensive overview of the genotype and phenotype patterns of CRPA in Japan is lacking. Herein, we conducted genome sequencing and quantitative antimicrobial susceptibility testing for 382 meropenem-resistant CRPA isolates that were collected from 78 hospitals across Japan from 2019 to 2020. CRPA exhibited susceptibility rates of 52.9%, 26.4%, and 88.0% against piperacillin–tazobactam, ciprofloxacin, and amikacin, respectively, whereas 27.7% of CRPA isolates was classified as difficult-to-treat resistance P. aeruginosa . Of the 148 sequence types detected, ST274 (9.7%) was predominant, followed by ST235 (7.6%). The proportion of urine isolates in ST235 was higher than that in other STs ( P = 0.0056, χ 2 test). Only 4.1% of CRPA isolates carried the carbapenemase genes: bla GES (2) and bla IMP (13). One ST235 isolate carried the novel bla IMP variant bla IMP-98 in the chromosome. Regarding chromosomal mutations, 87.1% of CRPA isolates possessed inactivating or other resistance mutations in oprD , and 28.8% showed mutations in the regulatory genes ( mexR , nalC , and nalD ) for the MexAB-OprM efflux pump. Additionally, 4.7% of CRPA isolates carried a resistance mutation in the PBP3-encoding gene ftsI . The findings from this study and other surveillance studies collectively demonstrate that CRPA exhibits marked genetic diversity and that its multidrug resistance in Japan is less prevailed than in other regions. This study contributes a valuable data set that addresses a gap in genotype/phenotype information regarding CRPA in the Asia–Pacific region, where the epidemiological background markedly differs between regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaMicrobial Sensitivity TestsCarbapenemsAnti-Bacterial AgentsBacterial ProteinsPseudomonas InfectionsJapanHumansbeta-LactamasesGenome, BacterialPiperacillin, Tazobactam Drug CombinationWhole Genome SequencingMeropenemDrug Resistance, Multiple, BacterialAmikacin

Stichwörter der Autor:innen

DTR-P. aeruginosaIMPSEcarbapenemaseintegron

Substanzen

CarbapenemsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemasePiperacillin, Tazobactam Drug CombinationMeropenemAmikacin

Autor:innen und Institutionen

  • Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan.

ORCID-Profile: Hirokazu Yano, Wataru Hayashi, Norikazu Kitamura, Aki Hirabayashi, Toshiki Kajihara, Shizuo Kayama, Yo Sugawara, Koji Yahara, Motoyuki Sugai

Förderung

  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Yano, H., Hayashi, W., Kawakami, S., Aoki, S., Anzai, E., Zuo, H., Kitamura, N., Hirabayashi, A., Kajihara, T., Kayama, S., Sugawara, Y., Yahara, K., & Sugai, M. (2024). Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan. Antimicrobial Agents and Chemotherapy, 68(5). https://doi.org/10.1128/aac.01669-23

Vancouver

Yano H, Hayashi W, Kawakami S, Aoki S, Anzai E, Zuo H, et al. Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan. Antimicrobial Agents and Chemotherapy. 2024;68(5). doi:10.1128/aac.01669-23

BibTeX
@article{Yano2024,
  author = {Yano, Hirokazu and Hayashi, Wataru and Kawakami, Sayoko and Aoki, Sadao and Anzai, Eiko and Zuo, Hui and Kitamura, Norikazu and Hirabayashi, Aki and Kajihara, Toshiki and Kayama, Shizuo and Sugawara, Yo and Yahara, Koji and Sugai, Motoyuki},
  title = {Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {5},
  doi = {10.1128/aac.01669-23}
}
Kostenlos starten →